$GILD

Daniel O'Day

Gilead Sciences

Chairman & CEO • Since 2019 • Health Care

Also profiled in: S&P 500

📊 CEO Reputation Score

FY2025 vs FY2024 · Source: SEC EDGAR filings

62/100

Blend of this company's year-over-year free-cash-flow and profit improvement, each ranked as a percentile against every scored company in the three indexes.

Free cash flow: $10.3B → $9.5B (−8.2% YoY) — fiscal 2025 vs fiscal 2024
Profit (net income): $480M → $8.5B (+1672.9% YoY) — fiscal 2025 vs fiscal 2024

How this score works · Nasdaq-100 reputation leaderboard

Overview

Daniel O'Day is the chairman & ceo of Gilead Sciences since 2019. Gilead Sciences is a Health Care company, and one of the 100 companies in the Nasdaq-100 — every one of which is profiled on this site.

Leadership

Daniel holds the chief executive role at Gilead Sciences with the title Chairman & CEO — in post since 2019. This page is the concise leadership record for Gilead Sciences in the Nasdaq-100 CEO index; the site's fully researched long-form profiles (career timelines, education, achievements, setbacks, philosophy and sourced quotes) currently cover the index's ten largest companies, and this entry will be expanded in the same format.

At a Glance

Sector: Health Care
Ticker: $GILD
CEO since: 2019
Index: Nasdaq-100 (#42 of 100)